Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Bristol-Myers Squibb Co’s stock clocked out at $47.85, up 2.79% from its previous closing price of $46.55. In other words, the price has increased by $2.79 from its previous closing price. On the day, 10.11 million shares were traded. BMY stock price reached its highest trading level at $47.87 during the session, while it also had its lowest trading level at $46.35.
Ratios:
To gain a deeper understanding of BMY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.68. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.92 whereas as Long-Term Debt/Eq ratio is at 2.64.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $55 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 02 ’25 when Short Bartie Wendy sold 378 shares for $44.23 per share. The transaction valued at 16,719 led to the insider holds 5,066 shares of the business.
Hickey Benjamin sold 97 shares of BMY for $3,702 on May 09 ’25. The President, RayzeBio Org. now owns 0 shares after completing the transaction at $38.01 per share. On Apr 25 ’25, another insider, Hirawat Samit, who serves as the EVP,Chief Med.Offr.,Drug Dev. of the company, bought 4,250 shares for $47.58 each. As a result, the insider paid 202,215 and bolstered with 83,513 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 97395802112 and an Enterprise Value of 132189536256. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.31, and their Forward P/E ratio for the next fiscal year is 7.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.04 while its Price-to-Book (P/B) ratio in mrq is 5.58. Its current Enterprise Value per Revenue stands at 2.771 whereas that against EBITDA is 6.916.
Stock Price History:
The Beta on a monthly basis for BMY is 0.36, which has changed by -0.0256567 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.96. The 50-Day Moving Average of the stock is 1.25%, while the 200-Day Moving Average is calculated to be -10.28%.
Shares Statistics:
It appears that BMY traded 13.69M shares on average per day over the past three months and 15197770 shares per day over the past ten days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 82.20% stake in the company. Shares short for BMY as of 1753920000 were 30920136 with a Short Ratio of 2.26, compared to 1751241600 on 39446776. Therefore, it implies a Short% of Shares Outstanding of 30920136 and a Short% of Float of 1.52.
Dividends & Splits
With its trailing 12-month dividend rate of 2.46, BMY has a forward annual dividend rate of 2.46. Against a Trailing Annual Dividend Yield of 0.052846402The stock’s 5-year Average Dividend Yield is 3.67.
Earnings Estimates
The market rating for Bristol-Myers Squibb Co (BMY) is a result of the insights provided by 20.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $1.58, with high estimates of $1.73 and low estimates of $1.33.
Analysts are recommending an EPS of between $6.64 and $6.26 for the fiscal current year, implying an average EPS of $6.52. EPS for the following year is $6.03, with 26.0 analysts recommending between $6.83 and $4.94.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $11.75B. It ranges from a high estimate of $12.06B to a low estimate of $11.48B. As of the current estimate, Bristol-Myers Squibb Co’s year-ago sales were $11.89BFor the next quarter, 18 analysts are estimating revenue of $12B. There is a high estimate of $12.26B for the next quarter, whereas the lowest estimate is $11.69B.
A total of 25 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $47.63B, while the lowest revenue estimate was $46.1B, resulting in an average revenue estimate of $47.22B. In the same quarter a year ago, actual revenue was $48.3BBased on 25 analysts’ estimates, the company’s revenue will be $43.43B in the next fiscal year. The high estimate is $45.49B and the low estimate is $41.43B.
